利用者の認知特性から見た病院の廊下・空間の構成に関する研究

本研究は、診療の目的ではなく患者の滞在が許される空間や場所、患者のアクセスが保証され、機能上の名前が付いていない空間や場所、あるいは廊下やホ-ルそものを「患者空間」と名づけ、患者あるいは他の利用者の心理や意識、個人にとっての空間の意味を考察することを試みている。第1章では、序論としてこれまでの建築計画研究に代わる視点を示した。第2章では、入院患者が新たに病院で入院生活を始める場合、どのようにその環境を理解し、各々の意識上に病院の諸空間を再構成していくかを少数の事例ではあるが、ひとりひとりの患者の意識や行動を環境との関係を通して記述的にとらえた。第3章では、患者を取り巻く様々な環境と患者の行動、患者空間の諸側面や属性などを患者の意識や行動、滞在様態に関する調査分析から、(1)患者の意識上に再構築される様々な空間や場所と、患者の環境行動(2)患者空間の意味変化や機能分化(3)患者の日常環境行動を支援できる仕掛けとしての患者空間のあり方を考察した。第4章では、システムやプログラムなどが日本とは異なる韓国の病院で、患者空間に対する患者の意識や行動、または患者の意識上に再構築される様々な空間や場所が患者が環境を理解して生活していく上でどのように寄与しているかを調べた。その結果を日本の病院でみられた患者の環境行動特性や患者空間の諸属性と比較することで、係る環境の違いと患者の意識や行動、患者空間のあり方との関連を探った。最後に第5章では、各章での分析や考察を踏まえた上で、概念的に扱ってきた地理的環境(Hospital Geography)を改めて考察し、「患者空間」が、日々変化する病院建築の中でどのように位置づけられ、患者や利用者の行動に寄与できるかを探った。科学研究費補助金 研究種目:一般研究(B)(2) 課題番号:06452303 研究代表者:山下 哲郎 研究期間:1994-1996年度research repor

Antibiotic-resistant Escherichia coli isolated from dairy cows and their surrounding environment on a livestock farm practicing prudent antimicrobial use

application/pdfOn a livestock farm where antimicrobial administration and its history had been managed for prudent use of antimicrobials, we surveyed antibiotic-resistant Escherichia coli strains isolated from cow feces and the surrounding environment （i.e., rat and crow feces, and water samples from a drainage pit and wastewater processing tank） every month for 1 year. Two strains （1.7%） in cow feces were resistant to tetracycline, whereas all other strains were susceptible to all other antimicrobials. Among 136 strains isolated from cows and wild animals, only one ampicillin-resistant strain was identified. The antibiotic resistance rate in the drainage from the barn was 8.3% （10/120）, and all strains showed susceptibility for 8 months of the year. Tetracycline resistance was common in all resistant strains isolated from animal feces and water samples; all tetracycline-resistant strains carried tetA. These results strongly support the proper use and management of antibiotics on farms to minimize the outbreak and spread of antibiotic-resistant bacteria

Observation of the ηc(2S) in Exclusive B→KKSK-π+ Decays

journal articl

Modification Effect of La on the Adsorption Behavior of CH_4 on MgO

application/pdfThe modification effect of La on CH_4-adsorption was examined. In the presence of surface OH， exposure of CH_4 caused the production of RCO species on MgO， while olefinic species was mainly produced on La-doped MgO. In the case of CH_4-pretreated surface， ammonia formed NCO species on MgO， not on La-doped MgO. We conclude that the higher selectivity of C_2 compounds in oxidative coupling of methane on La-doped MgO is ascribed to La's inhibition effect on breaking olefinic C-C bond produced from CH_4 ； this breaking forms RCO species leading to CO_x species.departmental bulletin pape

グローバリゼーションの中の日本語 : その感性と活力

departmental bulletin pape

Characterization of P-TEFb retention by HeLa cell nuclei using differential salt extraction

<p><b>Copyright information:</b></p><p>Taken from "Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex"</p><p>http://www.retrovirology.com/content/4/1/47</p><p>Retrovirology 2007;4():47-47.</p><p>Published online 11 Jul 2007</p><p>PMCID:PMC1948018.</p><p></p> Untreated HeLa cells and HeLa cells treated for 1 hour with 100 μM DRB were lysed with a buffer containing the indicated amounts of NaCl to generate cytosolic extracts (CE). The CE and the nuclear pellet (NP) were examined by immunoblotting with the indicated antibodies for the presence of P-TEFb or the TFIIH components p62, Cdk7 and cyclin H

The P-TEFb inhibitors DRB, seliciclib and flavopiridol release P-TEFb from the large form

<p><b>Copyright information:</b></p><p>Taken from "Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex"</p><p>http://www.retrovirology.com/content/4/1/47</p><p>Retrovirology 2007;4():47-47.</p><p>Published online 11 Jul 2007</p><p>PMCID:PMC1948018.</p><p></p> Low-salt cytosolic extract (CE) containing the large form of P-TEFb and high-salt nuclear extracts (NE) containing the free form of P-TEFb were generated from (A) DRB-treated HeLa cells, (B) DRB treated Jurkat cells, (C) seliciclib-treated HeLa37 cells or (D) flavopiridol-treated Jurkat cells. Quantitative western blotting was performed on low salt cytosolic extracts (CE) and high-salt nuclear extracts (NE) to detect the percentage of Cdk9 and cyclin T1 present in the free and large form of the P-TEFb complex. The percent of P-TEFb in the large form of the complex (low-salt or CE) was calculated as a fraction of the total amount of P-TEFb (low-salt + high-salt P-TEFb) and plotted as a function of the concentration of P-TEFb inhibitor

Inhibition of HIV-1 infectivity by non-cytotoxic concentrations of the P-TEFb inhibitors DRB, seliciclib and flavopiridol

<p><b>Copyright information:</b></p><p>Taken from "Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex"</p><p>http://www.retrovirology.com/content/4/1/47</p><p>Retrovirology 2007;4():47-47.</p><p>Published online 11 Jul 2007</p><p>PMCID:PMC1948018.</p><p></p> HeLa37 cells were infected with HIV-1and treated with the indicated amounts of (A) DRB, (B) seliciclib and (C) flavopiridol. After 40 hours the cells were fixed, immunostained for HIV antigens and the number of HIV positive cells counted. The number of infected cells (solid circles) was normalized to the control infection and plotted. Cell viability studies were performed in parallel. Values form cytotoxicity studies (open circles) were normalized to the mock treated cells and plotted